Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from...
Potential first-in-class
Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241
US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre,...
Lynk Pharmaceuticals Concludes Phase I Study for JAK Inhibitor LNK01003 with Positive Results
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I...
Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma
China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification
China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...
Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU
China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca
China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...
Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...